Outlook Therapeutics, Inc. (OTLK)
Stock Price:
$1.40 USD
0.06 (4.48%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
172.43M |
| Revenue (ttm) |
6.44M |
| Net Income (ttm) |
-36.84M |
| Shares Out |
123.17M |
| EPS (ttm) |
-1.57 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$1.40 |
| Previous Close |
$1.34 |
| Change ($) |
0.06 |
| Change (%) |
4.48% |
| Day's Open |
1.33 |
| Day's Range |
1.32 - 1.49 |
| Day's Volume |
5,732,773 |
| 52-Week Range |
0.50 - 2.19 |
More Stats
| Market Cap |
172.43M |
| Enterprise Value |
178.71M |
| Earnings Date (est) |
Dec 16, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
123.17M |
| Float |
39.94M |
| EPS (basic) |
-1.42 |
| EPS (diluted) |
-1.57 |
| FCF / Share |
-0.63 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.14M |
| Short Ratio |
0.69 |
| Short % of Float |
2.03% |
| Beta |
0.36 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
26.79 |
| PB Ratio |
n/a |
| Revenue |
6.44M |
| Operating Income |
-33.28M |
| Net Income |
-36.84M |
| Free Cash Flow |
-30.14M |
| Net Cash |
-6.28M |
| Net Cash / Share |
-0.05 |
| Gross Margin |
-243.25% |
| Operating Margin |
-517.04% |
| Profit Margin |
-789.10% |
| FCF Margin |
-468.20% |
| ROA |
-100.94% |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$6.31*
(350.71% upside)
Low
3.25
Current: $1.40
High
9.00
Target: 6.31
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 8.15 | 3.09 | 3.81 | 2.98 | 5.22 | 9.05 |
| Revenue Growth | 163.84% | -18.99% | 27.92% | -42.91% | -42.33% | - |
| Gross Profit | 8.15 | 3.09 | 3.81 | 2.98 | 5.22 | 9.05 |
| Operating Income | -36.30 | -29.64 | -35.88 | -51.35 | -46.56 | -12.39 |
| Net Income | -34.52 | -30.09 | -38.85 | -53.30 | -47.39 | -13.73 |
| Shares Outstanding | 18.19 | 4.93 | 3.00 | 2.15 | 1.22 | 1.06 |
| Earnings Per Share | -1.98 | -9.74 | -14.40 | -29.36 | -43.44 | -19.44 |
| Operating Cash Flow | -32.29 | -33.04 | -15.51 | -45.48 | -27.48 | -7.02 |
| Capital Expenditures | -0.44 | -2.78 | -0.29 | -1.10 | -8.80 | -2.37 |
| Free Cash Flow | -32.73 | -35.82 | -15.80 | -46.58 | -36.28 | -9.39 |
| Cash & Equivalents | 8.02 | 1.72 | 3.19 | 2.57 | 9.28 | 2.56 |
| Total Debt | 11.33 | 17.32 | 13.80 | 4.12 | 19.96 | 15.17 |
| Net Cash / Debt | -3.32 | -15.60 | -10.62 | -1.55 | -10.68 | -12.61 |
| Assets | 17.13 | 22.28 | 20.73 | 25.41 | 35.01 | 11.60 |
| Liabilities | 27.90 | 43.09 | 51.46 | 30.58 | 62.56 | 32.05 |
| Book Value | -16.13 | -25.54 | -33.65 | -5.17 | -54.22 | -45.15 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Outlook Therapeutics, Inc. |
| Country |
United States |
| Employees |
14 |
| CEO |
Lawrence A. Kenyon |
Stock Information
| Ticker Symbol |
OTLK |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: OTLK |
| IPO Date |
May 13, 2016 |
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was founded in 2010 and is headquartered in Cranbury, New Jersey.